spacer
home > ict > autumn 2018 > quality upkeep
PUBLICATIONS
International Clinical Trials

Quality Upkeep

To ensure a smooth transition from the pre-authorisation to the post-authorisation phase of the lifecycle of a medicinal product, the marketing authorisation (MA) applicant is responsible for ensuring a robust pharmacovigilance (PV) system is in place to monitor patient safety once the product is on the market. During clinical trials, patient exposure is limited and closely monitored, and very specific criteria must be met for patients who are eligible to take part in the study. However, once the product is on the market and more widely available, patient exposure will be much more widespread and patients may experience adverse reactions (ARs) that have not been observed previously in a clinical trial setting.

To maintain compliance with EU post-marketing regulatory requirements, the MA holder (MAH) must ensure that the following are in place:

• PV systems (including appropriate technology, quality management system, and PV processes)
• Qualified Person for PV (QPPV) and deputy and local safety-responsible representatives (where required under national legislation)
• PV system master file (PSMF)
• Risk management and minimisation systems
• Signal management • Global literature search strategy
• EudraVigilance (EV) maintenance, including Article 57 database

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
David Hukin is the Head of Pharmacovigilance and the PV team at Quanticate. David has a PhD in cell physiology and biophysics and 15 years’ experience in the pharmaceutical industry, with more than 14 years working in the PV sector. He has worked across speciality pharma/biotechnology companies and has gained preand post-marketing experience in a range of therapeutic areas, including gastroenterology, hepatology, neurology, oncology, psychiatric conditions, ATMPs, and orphan drug indication products for rare diseases. Since 2015, David has worked in the specialist PV service provider sector, leading multiple large teams responsible for clinical and post-marketing for customers ranging from small pharma/ biotech to large speciality and generic companies, before joining Quanticate in 2018.
spacer
David Hukin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

AstroNova introduces its range of grass paper labels derived from grass for high quality organic products

Dietzenbach, 29 April 2019, AstroNova GmbH, European headquarters of AstroNova Inc. (RI, USA), responsible for Sales and Customer Service in Europe, the Middle East and Africa (EMEA), is extending its Product Identification range with new approved labelling for direct foodstuff contact.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement